News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
125,165 Results
Type
Article (7354)
Company Profile (59)
Press Release (117752)
Multimedia
Podcasts (12)
Webinars (2)
Section
Business (38342)
Career Advice (88)
Deals (5949)
Drug Delivery (10)
Drug Development (23751)
Employer Resources (12)
FDA (3014)
Job Trends (3576)
News (68987)
Policy (4608)
Tag
Academia (326)
Accelerated approval (1)
Adcomms (10)
Allergies (3)
Alliances (11236)
ALS (9)
Alzheimer's disease (133)
Antibody-drug conjugate (ADC) (106)
Approvals (3054)
Artificial intelligence (83)
Autoimmune disease (4)
Automation (2)
Bankruptcy (57)
Best Places to Work (3306)
BIOSECURE Act (1)
Biosimilars (35)
Biotechnology (51)
Bladder cancer (63)
Brain cancer (22)
Breast cancer (210)
Cancer (1659)
Cardiovascular disease (17)
Career advice (77)
Career pathing (3)
CAR-T (71)
Cell therapy (163)
Cervical cancer (13)
Clinical research (19947)
Collaboration (343)
Company closure (1)
Compensation (114)
Complete response letters (1)
COVID-19 (322)
CRISPR (11)
C-suite (93)
Cystic fibrosis (2)
Data (791)
Decentralized trials (1)
Depression (6)
Diabetes (24)
Diagnostics (1319)
Digital health (3)
Diversity (1)
Diversity, equity & inclusion (5)
Drug discovery (44)
Drug pricing (10)
Drug shortages (1)
Duchenne muscular dystrophy (7)
Earnings (13228)
Editorial (9)
Employer branding (2)
Employer resources (13)
Events (23485)
Executive appointments (241)
FDA (3357)
Fibrodysplasia Ossificans Progressiva (1)
Frontotemporal dementia (1)
Funding (160)
Gene editing (19)
Generative AI (8)
Gene therapy (55)
GLP-1 (102)
Government (469)
Guidances (35)
Healthcare (4054)
Huntington's disease (2)
IgA nephropathy (5)
Immunology and inflammation (33)
Indications (14)
Infectious disease (343)
Inflammatory bowel disease (27)
Inflation Reduction Act (1)
Influenza (5)
Intellectual property (26)
Interviews (12)
IPO (2972)
IRA (7)
Job creations (483)
Job search strategy (69)
Kidney cancer (11)
Labor market (3)
Layoffs (128)
Leadership (3)
Legal (474)
Liver cancer (42)
Lung cancer (270)
Lymphoma (86)
Machine learning (2)
Management (3)
Manufacturing (46)
MASH (6)
Medical device (849)
Medtech (849)
Mergers & acquisitions (3114)
Metabolic disorders (63)
Multiple sclerosis (7)
NASH (1)
Neurodegenerative disease (6)
Neuropsychiatric disorders (1)
Neuroscience (208)
NextGen: Class of 2025 (952)
Non-profit (494)
Now hiring (7)
Obesity (32)
Opinion (31)
Ovarian cancer (62)
Pain (8)
Pancreatic cancer (57)
Parkinson's disease (20)
Partnered (1)
Patents (41)
Patient recruitment (31)
Peanut (2)
People (12983)
Pharmaceutical (14)
Pharmacy benefit managers (1)
Phase I (7529)
Phase II (8397)
Phase III (6406)
Pipeline (465)
Policy (18)
Postmarket research (472)
Preclinical (2366)
Press Release (2)
Prostate cancer (77)
Psychedelics (2)
Radiopharmaceuticals (162)
Rare diseases (62)
Real estate (735)
Recruiting (5)
Regulatory (4167)
Reports (8)
Research institute (663)
Resumes & cover letters (11)
RSV (8)
Schizophrenia (16)
Series A (34)
Series B (10)
Service/supplier (1)
Sickle cell disease (19)
Special edition (1)
Spinal muscular atrophy (16)
Sponsored (3)
Startups (753)
State (1)
Stomach cancer (10)
Supply chain (6)
Tariffs (4)
The Weekly (12)
Vaccines (125)
Venture capitalists (13)
Weight loss (16)
Women's health (1)
Date
Today (44)
Last 7 days (248)
Last 30 days (863)
Last 365 days (8748)
2025 (3119)
2024 (9489)
2023 (10666)
2022 (13132)
2021 (13181)
2020 (10961)
2019 (8592)
2018 (6333)
2017 (7124)
2016 (6284)
2015 (6948)
2014 (4524)
2013 (3091)
2012 (3341)
2011 (3329)
2010 (3038)
Location
Africa (83)
Alabama (19)
Alaska (1)
Arizona (18)
Arkansas (2)
Asia (10740)
Australia (1439)
California (1741)
Canada (436)
China (285)
Colorado (51)
Connecticut (72)
Delaware (115)
Europe (19749)
Florida (218)
Georgia (8)
Idaho (6)
Illinois (164)
India (8)
Indiana (51)
Iowa (3)
Japan (75)
Kansas (8)
Kentucky (9)
Maine (3)
Maryland (218)
Massachusetts (1451)
Michigan (17)
Minnesota (67)
Missouri (6)
Montana (5)
Nebraska (2)
Nevada (8)
New Hampshire (7)
New Jersey (472)
New Mexico (3)
New York (424)
North Carolina (174)
Northern California (851)
Ohio (46)
Oklahoma (1)
Oregon (5)
Pennsylvania (272)
Rhode Island (4)
South America (113)
South Carolina (2)
Southern California (675)
Tennessee (15)
Texas (292)
United States (6046)
Utah (47)
Virginia (15)
Washington D.C. (5)
Washington State (169)
Wisconsin (13)
125,165 Results for "gritstone oncology".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Bankruptcy
Gritstone Files for Bankruptcy in Effort to Save Clinical Research
Vaccine biotech Gritstone bio is filing for bankruptcy while securing a stalking horse bid from an unnamed party, which the company hopes will save its clinical research in cancer and infectious disease.
October 10, 2024
·
1 min read
·
Annalee Armstrong
Business
Gritstone bio Announces Appointment of Stephen Webster to its Board of Directors
Gritstone bio, Inc. today announced the appointment of Stephen Webster to its Board of Directors.
April 29, 2024
·
5 min read
Biotech Bay
Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 13, 2024
Gritstone bio, Inc. announced that the Compensation Committee of the company’s Board of Directors granted one employee nonqualified stock options to purchase an aggregate of 6,850 shares of its common stock with an exercise price of $0.75, which is equal to the closing price of Gritstone’s common stock on June 7, 2024, the date of the grant.
June 13, 2024
·
1 min read
Biotech Bay
Gritstone bio to Participate in Upcoming Investor and Scientific Conferences - April 8, 2024
Gritstone bio, Inc. today announced that management will be participating in the following investor and scientific conferences.
April 8, 2024
·
1 min read
Biotech Bay
Gritstone bio to Participate in Upcoming Investor and Scientific Conferences - June 04, 2024
Gritstone bio, Inc., a clinical-stage biotechnology company working to develop the world’s most potent vaccines, announced that management will be participating in the following investor and scientific conferences.
June 4, 2024
·
1 min read
Biotech Bay
Gritstone bio to Participate in Upcoming Investor Conference
Gritstone bio, Inc. today announced that management will be participating in the following investor conference.
January 17, 2024
·
1 min read
Business
Gritstone bio Announces Workforce Reduction
Gritstone bio, Inc., a clinical-stage biotechnology company working to develop the world’s most potent vaccines, announced an approximately 40% reduction of its workforce.
February 29, 2024
·
3 min read
Biotech Bay
Gritstone bio to Participate in Upcoming Investor and Scientific Conferences
Gritstone bio, Inc. today announced that management will be participating in the following investor and scientific conferences.
February 21, 2024
·
1 min read
Biotech Bay
Gritstone bio Presents Improvements to EDGE™ Platform at AACR 2024
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today presented an update on its T cell epitope discovery platform, EDGE, at the 2024 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA.
April 8, 2024
·
6 min read
Drug Development
Gritstone Fails Cancer Vaccine Trial, Plans Phase III and Public Offering
The biotech’s personalized neoantigen vaccine for colorectal cancer did not demonstrate a molecular response difference from the control arm. Gritstone blames trial protocol and plans for a Phase III study.
April 2, 2024
·
2 min read
·
Kate Goodwin
1 of 12,517
Next